SCHEMBL16610855

SCHEMBL16610855

COc1cccc(-c2nn(C3CCCC3)c3cc[nH]c(=O)c23)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITK Q08881 1/20 0.43
PDE9A O76083 4/20 0.43
PDE4A P27815 3/20 0.41
PDE4B Q07343 3/20 0.41
PDE4C Q08493 3/20 0.41
PDE4D Q08499 3/20 0.41
BACE1 P56817 3/20 0.41
ABL1 P00519 2/20 0.40
EGFR P00533 2/20 0.40
SRC P12931 2/20 0.40
ABL2 P42684 1/20 0.40
PIK3CA P42336 3/20 0.40
KCNJ6 P48051 1/20 0.40
KCNJ5 P48544 1/20 0.40
KCNJ3 P48549 1/20 0.40
PKM P14618 1/20 0.40
GAA P10253 1/20 0.39
PIK3CD O00329 1/20 0.39
HCK P08631 1/20 0.39
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16611267 0.87 CMKLR1 (0.42) ITKPDE9AABL1EGFRSRC
SCHEMBL16611850 0.84 JAK2 (0.42) ABL1EGFRSRCPIK3CAPIK3CD
SCHEMBL16611757 0.83 JAK2 (0.47) PDE4APDE4BPDE4CPDE4DABL1
SCHEMBL18052609 0.81 PIK3CD (0.40) ABL1EGFRSRCPIK3CAPIK3CD
SCHEMBL16610614 0.81 EGFR (0.43) ITKABL1EGFRSRCPIK3CA
SCHEMBL16610945 0.81 JAK2 (0.44) EGFRKCNJ6KCNJ5KCNJ3
SCHEMBL16611159 0.81 PDE4D (0.42) ITKPDE4DABL1EGFRSRC
SCHEMBL16610873 0.80 JAK2 (0.45) PDE4DABL1EGFRSRCPIK3CA
SCHEMBL16610948 0.78 PIK3CD (0.40) ABL1EGFRSRCPIK3CAPIK3CD
SCHEMBL16611153 0.78 JAK1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 ITK 3725/4885PDE9A 1708/4885PDE4A 2123/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 ITK 3725/4885PDE9A 1708/4885PDE4A 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.